Video

Pharmacist Medication Insights: Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

Lefamulin (Xenleta, Nabriva Therapeutics) is approved for the treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms.

In 2019, the FDA approved lefamulin (Xenleta, Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.

Lefamulin demonstrates in vitro activity against the most common atypical, gram-negative, and gram-positive pathogens associated with CABP. To maintain its efficacy and reduce the development of drug-resistant bacteria, treatment should be used only in patients with infections that are proven or strongly suspected to be caused by bacteria. It is available in both intravenous and oral formulations.

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Image credit: Photo18@desing | stock.dobe.com